ValiRx 과거 수익 실적
과거 기준 확인 0/6
ValiRx has been growing earnings at an average annual rate of 3.5%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 95.1% per year.
주요 정보
3.5%
수익 성장률
72.9%
EPS 성장률
Biotechs 산업 성장 | -14.6% |
매출 성장률 | 95.1% |
자기자본 수익률 | -58.9% |
순이익 | -20,554.0% |
최근 수익 업데이트 | 30 Jun 2024 |
최근 과거 실적 업데이트
Recent updates
수익 및 비용 분석
ValiRx 수익 창출 및 지출 방식. 최근 보고된 수익 기준, LTM 기준.
수익 및 매출 내역
날짜 | 수익 | 수익 | G+A 비용 | R&D 비용 |
---|---|---|---|---|
30 Jun 24 | 0 | -2 | 2 | 0 |
31 Mar 24 | 0 | -2 | 2 | 0 |
31 Dec 23 | 0 | -2 | 2 | 0 |
30 Sep 23 | 0 | -2 | 2 | 0 |
30 Jun 23 | 0 | -2 | 2 | 1 |
31 Mar 23 | 0 | -2 | 2 | 1 |
31 Dec 22 | 0 | -2 | 2 | 1 |
30 Sep 22 | 0 | -2 | 2 | 0 |
30 Jun 22 | 0 | -2 | 2 | 0 |
31 Mar 22 | 0 | -2 | 2 | 0 |
31 Dec 21 | 0 | -2 | 1 | 0 |
30 Sep 21 | 0 | -1 | 1 | 0 |
30 Jun 21 | 0 | -1 | 1 | 0 |
31 Mar 21 | 0 | -1 | 1 | 0 |
31 Dec 20 | 0 | -1 | 1 | 0 |
30 Sep 20 | 0 | -2 | 2 | 1 |
30 Jun 20 | 0 | -2 | 2 | 1 |
31 Mar 20 | 0 | -2 | 2 | 1 |
31 Dec 19 | 0 | -2 | 2 | 1 |
30 Sep 19 | 0 | -3 | 2 | 1 |
30 Jun 19 | 0 | -3 | 2 | 1 |
31 Mar 19 | 0 | -4 | 2 | 1 |
31 Dec 18 | 0 | -4 | 3 | 2 |
30 Sep 18 | 0 | -4 | 2 | 2 |
30 Jun 18 | 0 | -3 | 2 | 2 |
31 Mar 18 | 0 | -3 | 2 | 2 |
31 Dec 17 | 0 | -3 | 1 | 2 |
30 Sep 17 | 0 | -4 | 2 | 2 |
30 Jun 17 | 0 | -5 | 2 | 2 |
31 Mar 17 | 0 | -5 | 2 | 2 |
31 Dec 16 | 0 | -5 | 2 | 2 |
30 Jun 16 | 0 | -3 | 1 | 1 |
31 Mar 16 | 0 | -2 | 1 | 1 |
31 Dec 15 | 0 | -2 | 1 | 2 |
30 Sep 15 | 0 | -3 | 2 | 2 |
30 Jun 15 | 0 | -3 | 2 | 2 |
31 Mar 15 | 0 | -3 | 2 | 2 |
31 Dec 14 | 0 | -3 | 2 | 2 |
30 Sep 14 | 0 | -3 | 1 | 2 |
30 Jun 14 | 0 | -2 | 1 | 1 |
31 Mar 14 | 0 | -3 | 1 | 1 |
31 Dec 13 | 0 | -3 | 1 | 2 |
양질의 수익: EAJF is currently unprofitable.
이익 마진 증가: EAJF is currently unprofitable.
잉여현금흐름 대 수익 분석
과거 수익 성장 분석
수익추이: EAJF is unprofitable, but has reduced losses over the past 5 years at a rate of 3.5% per year.
성장 가속화: Unable to compare EAJF's earnings growth over the past year to its 5-year average as it is currently unprofitable
수익 대 산업: EAJF is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).
자기자본 수익률
높은 ROE: EAJF has a negative Return on Equity (-58.92%), as it is currently unprofitable.